Exchange Traded Concepts LLC Sells 37 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Exchange Traded Concepts LLC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,586 shares of the pharmaceutical company’s stock after selling 37 shares during the period. Exchange Traded Concepts LLC’s holdings in Vertex Pharmaceuticals were worth $1,151,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in VRTX. Brighton Jones LLC increased its position in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares in the last quarter. American Trust increased its position in Vertex Pharmaceuticals by 2.7% during the 4th quarter. American Trust now owns 1,503 shares of the pharmaceutical company’s stock valued at $605,000 after buying an additional 40 shares in the last quarter. Great Valley Advisor Group Inc. increased its position in Vertex Pharmaceuticals by 12.8% during the 4th quarter. Great Valley Advisor Group Inc. now owns 20,593 shares of the pharmaceutical company’s stock valued at $8,293,000 after buying an additional 2,343 shares in the last quarter. Armis Advisers LLC purchased a new stake in Vertex Pharmaceuticals during the 4th quarter valued at $359,000. Finally, Sculati Wealth Management LLC boosted its stake in Vertex Pharmaceuticals by 1.0% during the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company’s stock valued at $1,029,000 after purchasing an additional 25 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling

In other news, Director Bruce I. Sachs acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.0%

VRTX stock opened at $383.13 on Tuesday. The firm has a market cap of $98.23 billion, a P/E ratio of 27.39 and a beta of 0.44. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The company’s 50-day simple moving average is $412.66 and its 200-day simple moving average is $449.11.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the prior year, the firm earned ($12.83) EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on VRTX shares. Wells Fargo & Company upgraded Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price on the stock in a research note on Wednesday, August 6th. Raymond James Financial started coverage on Vertex Pharmaceuticals in a research note on Tuesday, September 2nd. They set a “market perform” rating on the stock. Wall Street Zen downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. HC Wainwright dropped their price target on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research note on Tuesday, August 5th. Finally, Morgan Stanley set a $439.00 price target on Vertex Pharmaceuticals and gave the stock an “equal weight” rating in a research note on Tuesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $496.05.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.